Tenon Medical’s stock dropped 11% as investors reacted negatively to cautious outlook signals overshadowing the revenue growth and margin expansion. Despite record first-quarter revenue and gross margin gains, elevated operating expenses and lack of clear forward guidance likely disappointed the market.

• Q1 revenue nearly doubled year-over-year to $1.4 million, driven by increased Catamaran procedure volumes and the first full quarter of SImmetry+ contribution.
• Gross margin expanded significantly to 68.5%, up 24 percentage points from a year ago, benefiting from higher revenue absorption of fixed overhead and streamlined commercial operations.
• Operating expenses rose slightly to $4.2 million, largely due to increased sales and marketing spend supporting the SImmetry+ rollout and higher R&D investment tied to product development.
• Net loss narrowed modestly to $3.5 million ($0.31 per share), with per-share improvement influenced by a larger share count but reflecting a real dollar loss reduction.
• No definitive upward guidance was provided for the near term; cost structure improvements may be offset by ongoing investment needs and potential growth execution risks.